Innovators from Global Biopharma Companies Discuss Consumer & Physician E-marketing Trends

Manhattan ResearchIn recent years European healthcare consumers and physicians have steadily increased their use of the Internet for treatment and product decisions. According to healthcare and pharmaceutical market research company's Manhattan Research's Cybercitizen Health™ Europe v8.0 study and strategy advisory service, over 150 million adults in countries across Europe used online channels to access health information in 2008.

In light of these trends, it's become necessary for biopharmaceutical companies to explore digital strategies in order to connect with target consumer and physician audiences at both a European and global level - however, they face a myriad of challenges in terms of regulations, process, and internal understanding.

To encourage innovation and knowledge-sharing across the industry, Manhattan Research releases its 2008 European Opinion Leader Roundtable report - a collection of opinions and best practices on key e-marketing and sales topics from innovators at AstraZeneca, UCB Pharma, Shire Pharmaceuticals, and Across Health. The virtual discussion is led by Manhattan Research President Mark Bard.

"Biopharma companies in Europe - and globally as well - can no longer afford to ignore 'e' channels as viable and cost-effective ways to reach consumer and physician groups," said Mr. Bard, "The key opinion leaders in this roundtable are catalysts for digital innovation within their respective organizations and offer valuable lessons learned and best practices for marketing and sales teams."

European Opinion Leader Roundtable Summary

Moderator:
Mark Bard, Manhattan Research

Opinion Leaders:
John Fish, AstraZeneca
Jean-Pierre Henskens, UCB Pharma
Gene Miller, Shire Pharmaceuticals
Fonny Schenck, Across Health

Topics:

  • Web-Empowered Healthcare Consumers
  • Facing Regulatory Challenges
  • Patient Compliance & Digital Strategy
  • Search Engine Marketing
  • Physicians & Closed Loop Marketing
  • Integration & Measurement
  • E-marketing Lessons Learned

The roundtable report is available to download on the Manhattan Research website. Please visit: http://www.manhattanresearch.com/research/roundtables/european-roundtable-2008.aspx.

Manhattan Research European Study & Strategic Advisory Service Products
Manhattan Research offers two European market research study & strategic advisory services for the healthcare and biopharmaceutical companies.

Cybercitizen Health™ Europe is focused on how European consumers use new media and technology for health information and its impact on treatment and product decisions. The latest study was conducted in Q3 2008 among 4,079 consumers in the United Kingdom, Germany, Spain, Italy, France, Belgium, Sweden, the Netherlands, Poland, and Portugal. Cybercitizen Health™ Europe identifies and analyses the behaviour, attitudes, and demographics of the consumer population who use technology and the Internet for health purposes, as well as further segmenting the population by therapeutic area, technology utilisation, and motivation. For more information, visit http://www.manhattanresearch.com/products/consumer/ccheu.aspx

Taking the Pulse® Europe is focused on how physicians across Europe use new media and technology for professional purposes. The next study will be available at the end of Q4 2008. Last year's study was fielded among 1,000 physicians from the United Kingdom, Germany, Spain, Italy, and France. Taking the Pulse® Europe provides pharmaceutical and healthcare companies with key data and insight about the evolving nature of physician channel mix, media and technology usage, and healthcare information with the goal of helping companies understand how physicians across Europe access health information. For more information, visit http://www.manhattanresearch.com/products/physician/EUphysicians.aspx

In addition to the core data, subscribing clients have access to the Manhattan Research analyst team and the ability to request country-specific therapeutic and specialist segmentations.

About Manhattan Research
Manhattan Research, a Decision Resources, Inc. company, is a leading market research and advisory services firm for global pharmaceutical and healthcare companies. For more information, visit http://www.manhattanresearch.com.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.DecisionResourcesInc.com.

Most Popular Now

COVID-19 can trigger self-attacking antibodies

Infection with the virus that causes COVID-19 can trigger an immune response that lasts well beyond the initial infection and recovery - even among people who had mild sy...

Stopping dementia at the nose with combination of …

Dementia is thought to occur when proteins called amyloid-β, tau, and α-synuclein accumulate in the brain and form oligomers. A research group from the Department of Tran...

Treatments in weeks, not months: Scientists develo…

An international team of scientists has created a plan for an accelerated pipeline for developing drug cocktails to battle the COVID-19 pandemic. The pipeline could speed...

COVID-19 - Omicron: resistant to most monoclonal a…

The Omicron variant was detected for the first time in South Africa in November 2021 and has since spread to many countries. It is expected to become the dominant variant...

Scientists identify antibodies that can neutralize…

An international team of scientists have identified antibodies that neutralize omicron and other SARS-CoV-2 variants. These antibodies target areas of the virus spike pro...

Pfizer and BioNTech sign new global collaboration …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a new research, development and commercialization collaboration to develop a potential first mRNA-based v...

Novartis and Molecular Partners report positive to…

Novartis and Molecular Partners announced that Part A of the EMPATHY clinical trial(1) that compared single intravenous doses of ensovibep, a DARPin antiviral therapeutic...

Bayer and Mammoth Biosciences to collaborate on no…

Bayer AG and Mammoth Biosciences, Inc., which is harnessing the diversity of nature to power the next-generation CRISPR products, today announced a strategic collaboratio...

Amgen and Arrakis Therapeutics announce multi-targ…

Amgen (NASDAQ:AMGN) and Arrakis Therapeutics today announced a research collaboration focused on the discovery and development of RNA degrader therapeutics against a rang...

Leiden University Medical Center and Intravacc to …

Intravacc, a global leader in translational research and development of therapeutic vaccines and vaccines against infectious diseases, today announced a partnership with ...

New Vaxzevria data further support its use as thir…

Positive results from a preliminary analysis of an ongoing safety and immunogenicity trial (D7220C00001) showed that Vaxzevria (ChAdOx1-S [Recombinant]), when given as a ...

AstraZeneca and Ionis close agreement to develop a…

AstraZeneca has closed a global development and commercialisation agreement with Ionis Pharmaceuticals, Inc. (Ionis) for eplontersen, formerly known as IONIS-TTR-LRX. ...